Trial Profile
Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Oct 2021
Price :
$35
*
At a glance
- Drugs Lu AF82422 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 05 Oct 2021 Status changed from recruiting to completed.
- 23 Feb 2021 Planned End Date changed from 1 Dec 2020 to 1 Aug 2021.
- 23 Feb 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Aug 2021.